Upstream Bio (NASDAQ:UPB) Research Coverage Started at TD Cowen

TD Cowen initiated coverage on shares of Upstream Bio (NASDAQ:UPB) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating on the stock.

Upstream Bio Trading Up 1.7 %

NASDAQ UPB opened at $27.02 on Tuesday. Upstream Bio has a 1 year low of $20.74 and a 1 year high of $29.46.

Insider Activity at Upstream Bio

In other news, major shareholder Ai Upstream Llc acquired 1,175,000 shares of Upstream Bio stock in a transaction on Tuesday, October 15th. The stock was bought at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the purchase, the insider now owns 1,175,000 shares of the company’s stock, valued at $19,975,000. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $19,975,000.00. Following the transaction, the insider now owns 1,175,000 shares in the company, valued at approximately $19,975,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Erez Chimovits bought 825,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the transaction, the director now owns 4,554,873 shares of the company’s stock, valued at $77,432,841. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.